Targeted Oncology
Advertisement
Articles by Targeted Oncology
Dr Mark Pegram and Dr Julie Gralow discuss treatment options in relapsed/refractory HER2+ metastatic breast cancer.
Key opinion leaders discuss the evolving treatment paradigm for relapsed/refractory gastrointestinal stromal tumors, and provide an overview of supplemental data presented at the ASCO (American Society of Clinical Oncology) 2020 Annual Meeting.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Ubamatamab Shows Durable Responses in Low-Grade Serous Ovarian Cancer
2
What Stood Out at IMS 2026? Five Myeloma Experts Weigh In
3
Pirtobrutinib Gains FDA Approval for Frontline CLL/SLL in Select Patients
4
Giredestrant Plus Everolimus Improves PFS in ER+ Advanced Breast Cancer
5